DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference

WILMINGTON, Mass., Sept. 22 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R) (Nasdaq: DUSA), a dermatology company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Maxim Group 3rd Annual Growth Conference on Tuesday, September 29, 2009 at 10:30 a.m. ET at The Grand Hyatt Hotel in New York City. Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan(R) PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(R). DUSA is researching the use of Levulan(R) PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.

SOURCE DUSA Pharmaceuticals, Inc.